Jaguar Health (NASDAQ:JAGX) Share Price Passes Above Fifty Day Moving Average – Here’s Why

Shares of Jaguar Health, Inc. (NASDAQ:JAGX) crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.18 and traded as high as $1.19. Jaguar Health shares last traded at $1.14, with a volume of 309,156 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised Jaguar Health from a “sell” rating to a “hold” rating in a report on Friday, September 13th.

Jaguar Health Price Performance

The company has a quick ratio of 1.60, a current ratio of 2.10 and a debt-to-equity ratio of 1.32. The firm has a fifty day simple moving average of $1.18 and a two-hundred day simple moving average of $4.54.

Jaguar Health (NASDAQ:JAGX) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($2.84). The business had revenue of $2.72 million during the quarter. Jaguar Health had a negative return on equity of 412.63% and a negative net margin of 350.18%. On average, equities analysts anticipate that Jaguar Health, Inc. will post -0.78 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Jaguar Health stock. Perritt Capital Management Inc acquired a new position in Jaguar Health, Inc. (NASDAQ:JAGX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned about 0.51% of Jaguar Health as of its most recent SEC filing. Institutional investors own 12.04% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.